Company / Operating Income
Celldex Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$287.4M
FY2025
5-year range
-$287.4M / -$71.2M
FY2021-FY2025
Trend
-47.3%
vs FY2024
Sector context
#144 of 156
Health Care
What the data says
Among 156 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 8% for operating income. Operating Income has declined for 6 consecutive years, from -$55M in FY2019 to -$287M in FY2025.
Based on SEC 10-K filings.
-$287M in FY2025.
Declined from -$155M to -$287M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 156This company -$287.4M Sector average $733.1M
▼
-139.2% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s operating income has declined for 6 consecutive years.
- In FY2025, operating income decreased 47.3% year-over-year.
- Ranks #144 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$287.4M | -47.3% |
| FY2024 | -$195.1M | -26.2% |
| FY2023 | -$154.5M | -34.1% |
| FY2022 | -$115.2M | -61.7% |
| FY2021 | -$71.2M | -12.5% |
| FY2020 | -$63.4M | -15.1% |
| FY2019 | -$55.0M | +58.6% |
| FY2018 | -$132.9M | -9.4% |
| FY2017 | -$121.5M | +8.6% |
| FY2016 | -$132.9M | -2.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026